unlicensed CBU

Phase 2Biologic

NNew York Blood Center

unlicensed CBU is one of 20 biologic programs targeting Transplantation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TransplantationRecruiting

TransplantationPhase 2

Recruiting

Competition

Competitive Landscape

23 competitors in Transplantation

#DrugCompanyPhaseTrials

Atgam

Novartis

Phase 3

5 2

Rituxan

Roche

Phase 3

5 3

Olumiant

Eli Lilly

Phase 3

1 4

Fludara

Sanofi

Phase 2

14 5

Neupogen

EEastern Cooperative Oncology Group

Phase 3

3 6

Trexall

Jazz Pharmaceuticals

Phase 2

3 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

13 8

Alkeran

AApotex Inc.

Phase 2

13 9

Actemra

Roche

Phase 2

1 10

Keppra

UCB

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Transplantation1 trial

Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting·NNew York Blood Center·Phase 2·NCT01656603·9,999 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for unlicensed CBU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — unlicensed CBU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for unlicensed CBU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — New York Blood Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNew York Blood Center

unlicensed CBU

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Transplantation1 trial

References

Drug Info

Quick Facts

Related News